Glucose metabolism in Familial Hypobetalipoproteinemia

Recruiting

• Conditions: patients with familial hypobetalipoproteinemia and matched controls

• Registration Number: NL-OMON29272
• Lead Sponsor: -

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 16

Inclusion Criteria

1. Subjects with documented FHBL, who have liver steatosis (FHBL group).
Healthy subjects (control group), exactly matched for age, sex, body mass index, waist circumference and physical activity

Exclusion Criteria

1. Known any somatic illness, including neoplasm, metabolic or endocrine disorder, neurologic disorder, active infection, or recent surgical procedures within 3 months of study initiation.

2. Use of medication, which can influence glucose or FFA metabolism (insuline, anabolic steroids, growth hormone, testosteron, DHEA, statines, ACE-inhibitors, AII-antagonists, aspirin)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine in detail:<br /><br>1) Quantity of liver- and muscle triglycerides<br /><br>2) Body fat distribution<br /><br>3) hepatic insulin sensitivity<br /><br>4) peripheral insulin sensitivity <br /><br>5) intramyocellular differences regarding fatty acid handling<br>of drug-free subjects with FHBL as compared to healthy controls matched for age, sex, body mass index, waist circumference and physical activity.<br>

Secondary Outcome Measures

Name	Time	Method
Adiponectin levels and levels of different adiponectin forms in plasma.